VRG-145
/ VRG Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 09, 2026
Novamigra Therapeutics Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145
(Firstwordpharma Press Release)
- "The proceeds will support the completion of CMC (Chemistry, Manufacturing, and Controls) development, as well as the execution of the company’s first-in-human pharmacokinetic (PK) and safety Phase 1 study....Based on regulatory guidance, Novamigra has finalized the design of its first-in-human Phase 1 study, a 36 healthy volunteer trial designed to assess the pharmacokinetics and safety of VRG-145."
Financing • New P1 trial • Migraine
1 to 1
Of
1
Go to page
1